Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial.

Sverrisdottir A, Nystedt M, Johansson H, Fornander T

Breast cancer research and treatment20 Jan 2009Cited by 117 (Europe PMC)

PMID19153828DOI10.1007/s10549-009-0313-5PepBankPUB-19153828

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In chemotherapy-treated premenopausal breast cancer patients, menses were reported by 36% with goserelin versus 13% with tamoxifen one year after treatment.
In plain wordsIn chemotherapy-treated breast cancer patients, menstruation was reported more often after goserelin than after tamoxifen.
Peptide
Goserelin
Outcome
IncreaseMenses after treatment
Study
n: not reported in source
Comparator
Tamoxifen alone
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated · 2 yearsAs given in this study (human).
Measurements
Women reporting menses
36%
goserelin alone, 1 year after completed therapy
Women reporting menses
13%
tamoxifen alone, 1 year after completed therapy
Source sentences
Summary
One year after completed CMF- and endocrine therapy, 36% of the women in the goserelin group reported menses, compared to 7% in the goserelin plus tamoxifen group, 13% in the tamoxifen group and 10% of the controls.
2 context sentences(design, population, supporting numbers)
Summary · context
Node positive patients were assigned to CMF-(cyclophosphamide, methotrexate and 5-fluorouracil) chemotherapy in addition to endocrine therapy.
Summary · context
All patients were randomly assigned to receive 2 years of goserelin, goserelin plus tamoxifen, tamoxifen alone or no endocrine treatment.
Report a problemFND-1915382801
02HumanRandomized controlled trialEfficacy outcome
In chemotherapy-treated premenopausal breast cancer patients, menses were reported by 36% with goserelin versus 10% of controls one year after treatment.
In plain wordsIn chemotherapy-treated breast cancer patients, menstruation was reported more often after goserelin than after no endocrine treatment.
Peptide
Goserelin
Outcome
IncreaseMenses after treatment
Study
n: not reported in source
Comparator
No endocrine treatment
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated · 2 yearsAs given in this study (human).
Measurements
Women reporting menses
36%
goserelin alone, 1 year after completed therapy
Women reporting menses
10%
controls, no endocrine treatment, 1 year after completed therapy
Source sentences
Summary
One year after completed CMF- and endocrine therapy, 36% of the women in the goserelin group reported menses, compared to 7% in the goserelin plus tamoxifen group, 13% in the tamoxifen group and 10% of the controls.
2 context sentences(design, population, supporting numbers)
Summary · context
Node positive patients were assigned to CMF-(cyclophosphamide, methotrexate and 5-fluorouracil) chemotherapy in addition to endocrine therapy.
Summary · context
All patients were randomly assigned to receive 2 years of goserelin, goserelin plus tamoxifen, tamoxifen alone or no endocrine treatment.
Report a problemFND-1915382802
03HumanRandomized controlled trialEfficacy outcome
In chemotherapy-treated premenopausal breast cancer patients, menses occurred in 36% after goserelin alone versus 7% after goserelin plus tamoxifen, one year after treatment.
In plain wordsIn chemotherapy-treated breast cancer patients, menstruation occurred more often after goserelin alone than after goserelin plus tamoxifen.
Peptide
Goserelin
Outcome
IncreaseMenses after treatment versus combined endocrine therapy
Study
n: not reported in source
Comparator
Goserelin plus tamoxifen
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated · 2 yearsAs given in this study (human).
Measurements
Women reporting menses
36%
goserelin alone, 1 year after completed therapy
Women reporting menses
7%
goserelin plus tamoxifen, 1 year after completed therapy
Source sentences
Summary
One year after completed CMF- and endocrine therapy, 36% of the women in the goserelin group reported menses, compared to 7% in the goserelin plus tamoxifen group, 13% in the tamoxifen group and 10% of the controls.
2 context sentences(design, population, supporting numbers)
Summary · context
Node positive patients were assigned to CMF-(cyclophosphamide, methotrexate and 5-fluorouracil) chemotherapy in addition to endocrine therapy.
Summary · context
All patients were randomly assigned to receive 2 years of goserelin, goserelin plus tamoxifen, tamoxifen alone or no endocrine treatment.
Report a problemFND-1915382804
04HumanRandomized controlled trialEfficacy outcome
In chemotherapy-treated premenopausal breast cancer patients, menses occurred in 7% after goserelin plus tamoxifen versus 13% after tamoxifen alone, one year after treatment.
In plain wordsIn chemotherapy-treated breast cancer patients, menstruation occurred less often after goserelin plus tamoxifen than after tamoxifen alone.
Peptide
Goserelin
Outcome
DecreaseMenses after goserelin added to tamoxifen
Study
n: not reported in source
Comparator
Tamoxifen alone
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated · 2 yearsAs given in this study (human).
Measurements
Women reporting menses
7%
goserelin plus tamoxifen, 1 year after completed therapy
Women reporting menses
13%
tamoxifen alone, 1 year after completed therapy
Source sentences
Summary
One year after completed CMF- and endocrine therapy, 36% of the women in the goserelin group reported menses, compared to 7% in the goserelin plus tamoxifen group, 13% in the tamoxifen group and 10% of the controls.
2 context sentences(design, population, supporting numbers)
Summary · context
Node positive patients were assigned to CMF-(cyclophosphamide, methotrexate and 5-fluorouracil) chemotherapy in addition to endocrine therapy.
Summary · context
All patients were randomly assigned to receive 2 years of goserelin, goserelin plus tamoxifen, tamoxifen alone or no endocrine treatment.
Report a problemFND-1915382805
05HumanNon-randomized trialEfficacy outcome
In goserelin-treated women, menstruation increased one year after treatment versus at 24 months of treatment (P = 0.006).
In plain wordsIn goserelin-treated women, menstruation was more frequent one year after treatment than at 24 months of treatment.
Peptide
Goserelin
Outcome
IncreaseRecovery of menstruation
Study
n: not reported in source
Comparator
At 24 months of treatment
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated · 2 yearsAs given in this study (human).
Measurements
P value
0.006 unitless
goserelin group, proportion menstruating 1 year after treatment vs at 24 months of treatment
Source sentences
Summary
Among women treated with goserelin, there was a statistically significant increase in the proportion of menstruating women, 1 year after completed treatment compared to at 24 months of treatment (P = 0.006), in contrast to all other treatment groups, who were unchanged or more often amenorrheic.
2 context sentences(design, population, supporting numbers)
Summary · context
Node positive patients were assigned to CMF-(cyclophosphamide, methotrexate and 5-fluorouracil) chemotherapy in addition to endocrine therapy.
Summary · context
All patients were randomly assigned to receive 2 years of goserelin, goserelin plus tamoxifen, tamoxifen alone or no endocrine treatment.
Report a problemFND-1915382803

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.